SCHEMBL3190941

SCHEMBL3190941

Fc1ccccc1[N]c1ccccc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.41
NFE2L2 Q16236 2/20 0.39
MAPT P10636 7/20 0.38
NPC1 O15118 6/20 0.38
GAA P10253 4/20 0.38
MAPK1 P28482 2/20 0.38
KDM4E B2RXH2 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
LRRK2 Q5S007 1/20 0.38
SMN1; SMN2 Q16637 5/20 0.37
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
RAB9A P51151 4/20 0.37
LMNA P02545 3/20 0.37
USP2 O75604 1/20 0.37
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36
TAAR1 Q96RJ0 1/20 0.35
HPGD P15428 1/20 0.34
NFKB1 P19838 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10519500 0.85 ACHE (0.54) ACHEMAPTNPC1GAAMAPK1
SCHEMBL5537663 0.84 ALDH1A1 (0.39) ACHENFE2L2MAPTNPC1GAA
SCHEMBL28714238 0.81 MAPT (0.52) ACHENFE2L2MAPTNPC1GAA
SCHEMBL28714237 0.81 MAPT (0.52) ACHENFE2L2MAPTNPC1GAA
SCHEMBL306539 0.79
SCHEMBL3109129 0.78 ACHE (0.35) ACHENFE2L2MAPTNPC1GAA
SCHEMBL3110354 0.77
SCHEMBL14273550 0.77
SCHEMBL765156 0.77
SCHEMBL1547450 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050123778-A1 Polyolefins made by catalyst comprising a noncoordinating anion and articles comprising them EXXONMOBIL CHEMICAL PATENTS INC. 2005-06-09 US claimed
EP-1406761-A2 POLYOLEFINS MADE BY CATALYST COMPRISING A NONCOORDINATING ANION AND ARTICLES COMPRISING THEM ExxonMobil Chemical Patents, Inc., A Corporation of the State of Delaware (US) 2004-04-14 EP claimed
WO-2003000740-A2 POLYOLEFINS MADE BY CATALYST COMPRISING A NONCOORDINATING ANION AND ARTICLES COMPRISING THEM EXXONMOBIL CHEMICAL PATENTS INC. (US) 2003-01-03 WO claimed
EP-1406761-B1 POLYOLEFINS MADE BY CATALYST COMPRISING A NONCOORDINATING ANION AND ARTICLES COMPRISING THEM EXXONMOBIL CHEM PATENTS INC (US) 2016-11-02 EP disclosed
US-7659416-B2 Monomolecular conductive complex, conductive self-assembled film and assembly of electrode composed of metal and semiconductor making use of the same TOKYO INSTITUTE OF TECHNOLOGY (JP) 2010-02-09 US disclosed
EP-2048167-A2 First catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer Sumitomo Chemical Company, Limited (JP) 2009-04-15 EP disclosed
EP-2048168-A2 Process for producing catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer Sumitomo Chemical Company, Limited (JP) 2009-04-15 EP disclosed
EP-2048170-A2 Second catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer Sumitomo Chemical Company, Limited (JP) 2009-04-15 EP disclosed
EP-2048169-A2 Third catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer Sumitomo Chemical Company, Limited (JP) 2009-04-15 EP disclosed
US-7511104-B2 Polyolefins made by catalyst comprising a noncoordinating anion and articles comprising them EXXONMOBIL CHEMICAL PATENTS INC. (US) 2009-03-31 US disclosed
US-20090036698-A1 Monomolecular Conductive Complex, Conductive Self-Assembled Film and Assembly of Electrode Composed of Metal and Semiconductor Making Use of the Same TOKYO INSTITUTE OF TECHNOLOGY 2009-02-05 US disclosed
EP-1406761-A2 POLYOLEFINS MADE BY CATALYST COMPRISING A NONCOORDINATING ANION AND ARTICLES COMPRISING THEM ExxonMobil Chemical Patents, Inc., A Corporation of the State of Delaware (US) 2004-04-14 EP disclosed
US-20030203810-A1 Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED 2003-10-30 US disclosed
US-6586356-B2 Coordination catalyst SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-07-01 US disclosed
WO-2003000740-A2 POLYOLEFINS MADE BY CATALYST COMPRISING A NONCOORDINATING ANION AND ARTICLES COMPRISING THEM EXXONMOBIL CHEMICAL PATENTS INC. (US) 2003-01-03 WO disclosed
US-20010020075-A1 Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-09-06 US disclosed
EP-1113026-A2 Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-07-04 EP disclosed
EP-0183191-B1 THIENYLTHIAZOLE COMPOUNDS Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1989-05-10 EP disclosed
US-4720493-A Thienylthiazole compounds YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1988-01-19 US disclosed
EP-0183191-A1 Thienylthiazole compounds Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1986-06-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036698-A1 Monomolecular Conductive Complex, Conductive Self-Assembled Film and Assembly of Electrode Composed of Metal and Semiconductor Making Use of the Same CNTN1, GAP43, AP3M1 ACHE 1129/4885NFE2L2 2408/4885MAPT 1911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.